In a special comment, Dr Brendan Shaw, the principal of Shawview Consulting, former CEO of MS and and assistant director-general of the IFPMA, says the PBS and Australian pharmaceutical policy have suffered some shocks in the past but nothing compares to COVID-19.
Latest Video
New Stories
-
Mark Butler announces the additon of another contraception option to the PBS
October 27, 2025 - - Latest News -
Medicines Australia hardens stance as US pressure sharpens spotlight on PBS pricing
October 26, 2025 - - Latest News -
Immuron launches PROIBS in Australia to support people living with IBS
October 24, 2025 - - Australian Biotech -
Queensland to host AusBiotech International Conference and sector leadership strengthened with director re-election
October 24, 2025 - - Australian Biotech -
David Henderson to Lead Takeda’s Specialty Franchise in Oceania
October 24, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 24, 2025 - - BioPharma -
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News
